慢性乙型肝炎病毒感染患者肝脏病理状态的定量抗HBc。

StephenW

Can J Infect Dis Med Microbiol. 2019 Dec 25;2019:6545642. doi: 10.1155/2019/6545642. eCollection 2019.
Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection.
Zhang ZQ1, Shi BS2, Lu W1, Liu DP1, Huang D1, Feng YL3.
Author information

1
    Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
2
    Scientific Research Center, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.
3
    Department of Clinical Pathology, Shanghai Public Health Clinical Center of Fudan University, Shanghai, China.

Abstract
Background:

Changes of hepatitis B core antigen antibody (anti-HBc) in liver pathological involvement in patients with chronic hepatitis B virus (HBV) infection have not been investigated in detail. This study aimed to explore evolving patterns of anti-HBc following liver pathological states and to investigate validities of anti-HBc for predicting liver pathological states.
Methods:

254 HBeAg-positive and 237 HBeAg-negative patients with chronic HBV infection were enrolled. Liver pathological diagnoses referred to Scheuer standard, and anti-HBc was measured using chemiluminescence microparticle immunoassay.
Results:

Anti-HBc was significantly positively correlated with pathological grades and stages in both HBeAg-positive (r s  = 0.312, P < 0.0001, and r s  = 0.268, P < 0.0001) and HBeAg-negative (r s  = 0.270, P < 0.0001, and r s  = 0.147, P=0.0237) patients. The medians of anti-HBc in pathological grades of G1, G2, and G3 and stages of S1, S2, S3, and S4 in HBeAg-positive patients were all significantly lower than those in HBeAg-negative patients (all P < 0.005). The areas under receiver-operating characteristic curves (95% confidence interval) of anti-HBc for predicting pathological grades ≥G2 and ≥G3, and stages ≥S2 and =S4 in HBeAg-positive patients were 0.683 (0.622-0.740) and 0.662 (0.601-0.720), and 0.627 (0.564-0.687) and 0.683 (0.622-0.740), respectively, and in HBeAg-negative patients were 0.681 (0.618-0.740) and 0.702 (0.639-0.760), and 0.569 (0.503-0.633) and 0.630 (0.565-0.691), respectively.
Conclusion:

Following hepatic aggravation of necroinflammation and progression of fibrosis, anti-HBc increases gradually in HBeAg-positive patients and continues to increase gradually in HBeAg-negative patients, which is a useful but unsatisfactory marker for monitoring pathological states.

Copyright © 2019 Zhan-qing Zhang et al.

PMID:
    31949546
PMCID:
    PMC6948315
DOI:
    10.1155/2019/6545642

StephenW

可以J感染Dis Med微生物。 2019年12月25日; 2019：6545642. Doi：10.1155 / 2019/6545642。 ECollection 2019。
慢性乙型肝炎病毒感染患者肝脏病理状态的定量抗HBc。
张ZQ1，施BS2，陆W1，刘DP1，黄D1，冯YL3。
作者信息

1个
复旦大学上海公共卫生临床中心肝胆内科，上海。
2
复旦大学上海公共卫生临床中心科研中心，上海
3
复旦大学上海公共卫生临床中心临床病理学系，上海

抽象
背景：

尚未详细研究慢性乙型肝炎病毒（HBV）感染患者肝病理学中乙型肝炎核心抗原抗体（anti-HBc）的变化。这项研究旨在探讨肝病理状态后抗HBc的演变模式，并研究抗HBc预测肝病理状态的有效性。
方法：

纳入254例HBeAg阳性和237例HBeAg阴性的慢性HBV感染患者。肝病理诊断参照Scheuer标准，并使用化学发光微粒免疫测定法测量抗HBc。
结果：

HBeAg阳性（rs = 0.312，P <0.0001，rs = 0.268，P <0.0001）和HBeAg阴性（rs = 0.270，P <0.0001，rs）的抗HBc与病理等级和分期显着正相关。 = 0.147，P = 0.0237）患者。 HBeAg阳性患者的病理分级为G1，G2和G3以及S1，S2，S3和S4阶段的抗HBc的中位数均显着低于HBeAg阴性患者（所有P <0.005）。 HBeAg阳性患者的抗HBc接收器工作特征曲线（95％置信区间）下预测病理等级≥G2和≥G3以及分期≥S2和= S4的区域分别为0.683（0.622-0.740）和0.662（分别为0.601-0.720）和0.627（0.564-0.687）和0.683（0.622-0.740），而在HBeAg阴性患者中分别为0.681（0.618-0.740）和0.702（0.639-0.760））和0.569（0.503-0.633） ）和0.630（0.565-0.691）。
结论：

随着肝坏死性炎症的加剧和纤维化的进展，HBeAg阳性患者的抗HBc逐渐增加，HBeAg阴性患者的抗HBc持续逐渐增加，这是监测病理状态的有用但不能令人满意的标志物。

版权所有©2019张占清等。

PMID：
31949546
PMCID：
PMC6948315
DOI：
10.1155 / 2019/6545642

StephenW

http://downloads.hindawi.com/journals/cjidmm/2019/6545642.pdf